#Pfizer #NovoNordisk #Metsera #EliLilly #BiotechNews #PharmaDeals #HealthcareInnovation #PharmaNews #ObesityDrugs #GLP1 #Amylin #WeightLossMarket #LifeSciences #PharmaceuticalIndustry #DrugDevelopment #HealthcareTrends #BusinessStrategy #MergersAndAcquisitions #MetabolicHealth #ClinicalResearch #Biopharma #InvestmentNews #RAndD #MedicalInnovation #DrugDiscovery #BiotechInvesting #GlobalPharma #HealthcareBusiness #MarketWatch #InnovationInHealth To view or add a comment, sign in Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk
Dr Shira Lakhani is the women for this job
Report sudden abdominal pain, persistent vomiting, or vision changes immediately
Ozempic is available in four different pre-filled, multi-dose syringe pen doses, including 0.25 mg (starting dose), 0.5 mg, 1.0 mg, and 2 mg (maximum dose)
A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 x FAD mice by modulating mitophagy via the PINK1/ Parkin pathway
10.1681/ASN.2018080862 46 PremontR
